Elkar solution for injection 100mg / ml, 5 ml No. 10

Special Price $25.48 Regular Price $33.00
In stock
SKU
BIDL3180136
509.6 Reward Points will be used to purchase this product

Expiration Date: 11/2025

Russian Pharmacy name:

Элькар раствор для инъекций 100мг/мл, 5 мл №10

Elkar solution for injection 100mg / ml, 5 ml No. 10

Elkar is used as part of complex therapy for acute hypoxic conditions (acute cerebral hypoxia, ischemic stroke, transient ischemic attack). The drug is prescribed in the acute, subacute and recovery periods of cerebrovascular accidents. Used for discirculatory encephalopathy and various traumatic and toxic brain lesions, in the recovery period after surgery. Elkar is indicated for primary and secondary carnitine deficiency, including in patients with chronic renal failure on hemodialysis; with cardiomyopathy, ischemic heart disease (angina pectoris, acute myocardial infarction, postinfarction conditions), hypoperfusion due to cardiogenic shock and other metabolic disorders in the myocardium.

1 amp. contains 0.5 g of active ingredient.

Intravenous, drip slowly or jet (2-3 min) or intramuscularly. Before intravenous administration, the contents of the ampoule are diluted in 100-200 ml of solvent (0.9% sodium chloride solution or 5% dextrose (glucose) solution.

In acute disorders of cerebral circulation - 1 g / day (2 amp.) For 3 days, and then - 0.5 g / day (1 amp.) For 7 days. After 10-12 days, repeated courses are possible for 3-5 days.

When prescribing the drug in the subacute and recovery period, with discirculatory encephalopathy and various brain lesions, carnitine deficiency, patients are injected with ElkarЃ at the rate of 0.5-1 g / day (1-2 amp.) IV (drip, jet) or i / m (2-3 times a day) without dilution for 3-7 days. If necessary, a second course is prescribed after 12-14 days.

IV injection, slowly (2-3 min), is prescribed for secondary carnitine deficiency during hemodialysis - 2 g (4 amp.) Once (after the procedure); in acute myocardial infarction, acute heart failure - 3-5 g / day (6-10 amp.), divided into 2-3 doses in the first 2-3 days, followed by a 2-fold dose reduction; in cardiogenic shock - 3-5 g / day (6-10 amp.), divided into 2-3 doses until the patient comes out of shock. Then they switch to oral administration of the drug ElkarЃ.

1 ml

active substance: levocarnitine (carniphite) -0.1 g

excipient: water for injection - up to 1 ml

Individual intolerance, pregnancy, lactation (there is currently no data on the possibility and safety of using the drug during pregnancy and lactation).

Trade name of the drug:

ElkarЃ

International non-proprietary name:

levocarnitine

Dosage form:

injection

Composition:

Carniphite (levocarnitine) 0.1 g; water for injection up to 1 ml.

Description:

transparent colorless liquid.

Pharmacotherapeutic group:

metabolic agent.

ATX code: A16AA01

Pharmacological properties

Elkar is a remedy for the correction of metabolic processes.

L-carnitine (a natural substance related to B vitamins) participates in metabolic processes as a carrier of fatty acids through the cell membranes from the cytoplasm to the mitochondria, where these acids are oxidized (beta-oxidation process) with the formation of a large amount of metabolic energy (in the form of ATP ). L-carnitine increases the resistance of the nervous tissue to damaging factors (hypoxia, trauma, intoxication, etc.), inhibits the formation of keto acids and anaerobic glycolysis, and reduces the degree of lactic acidosis. The drug replenishes the alkaline reserve of blood, helps to restore autoregulation of cerebral hemodynamics and increase the blood supply to the affected area, accelerates reparative processes in the lesion focus and has an anabolic effect.

Pharmacokinetics

After intravenous administration after 3 hours, it is almost completely eliminated from the blood. Easily penetrates the liver and myocardium, more slowly - into the muscles. It is excreted by the kidneys mainly in the form of acyl esters (more than 80% in 24 hours).

Indications for use

Elkar is used as part of complex therapy for acute hypoxic conditions (acute cerebral hypoxia, ischemic stroke, transient ischemic attack). The drug is prescribed in the acute, subacute and recovery periods of cerebrovascular accidents. Used for discirculatory encephalopathy and various traumatic and toxic brain lesions, in the recovery period after surgery. Elkar is indicated for primary and secondary carnitine deficiency, including in patients with chronic renal failure on hemodialysis; with cardiomyopathy, ischemic heart disease (angina pectoris, acute myocardial infarction, postinfarction conditions), hypoperfusion due to cardiogenic shock and other metabolic disorders in the myocardium.

Contraindications

Individual intolerance, pregnancy, lactation (there is currently no data on the possibility and safety of using the drug during pregnancy and lactation).

Method of administration and dosage

One ampoule contains 0.5 g of active ingredient.

ElkarЃ is injected intravenously slowly or in a stream (2-3 minutes) or intravenously. Before intravenous administration, the contents of the ampoule are dissolved in 100-200 ml of solvent (0.9% sodium chloride solution or 5% dextrose (glucose) solution).

In acute disorders of cerebral circulation, 1 g / day (2 ampoules) is prescribed for 3 days, and then 0.5 g / day (1 ampoule) for 7 days. After 10-12 days, repeated courses are possible for 3-5 days.

When prescribing the drug in the subacute and recovery period, with discirculatory encephalopathy and various brain lesions, carnitine deficiency, patients are injected with ElkarЃ solution at the rate of 0.5-1 g / day (1-2 ampoules) intravenously (drip, jet) or intravenously m (2-3 times a day) without dilution for 3-7 days. If necessary, a second course is prescribed after 12-14 days.

Intravenous administration, slowly (2-3 minutes) is prescribed for secondary carnitine deficiency during hemodialysis - 2 g (4 ampoules) once (after the procedure); in acute myocardial infarction, acute heart failure - 3-5 g / day (6-10 ampoules), divided into 2-3 doses in the first 2-3 days, followed by a 2-fold dose reduction; with cardiogenic shock - 3-5 g / day (6-10 ampoules), divided into 2-3 doses until the patient comes out of shock. Then they switch to oral administration of ElkarЃ.

Side effect

Allergic reactions, muscle weakness are possible (in patients with uremia). With a rapid introduction (80 drops / min or more), pain may occur along the vein, which disappears with a decrease in the rate of administration.

Interaction

Glucocorticosteroids promote the accumulation of the drug in tissues (except for the liver), other anabolic steroids enhance the effect.

Release form

Solution for injection 100 mg / ml. 5 ml of the drug in colorless glass ampoules with a dot or break ring. 10 ampoules are placed in a pack with partitions. Or 5 ampoules are placed in a blister made of polyvinyl chloride film. Two contour packs are placed in a cardboard box. Each pack contains instructions for the use of the drug.

Hospital packaging. 10 or 20 blister packs are placed in cardboard boxes or in corrugated cardboard boxes. Each box contains instructions for use in an amount equal to the number of blisters.

Storage conditions

In a dark place at a temperature of 15 to 25 ? C.

Keep out of the reach of children.

Shelf life

3 years. Do not use after the expiration date printed on the package.

Conditions of dispensing from pharmacies

On prescription.

Submit your review to Earn 10 Reward Points click here to login

Write Your Own Review
You're reviewing:Elkar solution for injection 100mg / ml, 5 ml No. 10

 Job in company (10-20 minutes a day | 400 - 1200 USD)! 

We are looking for partners!

 If you have PayPal and you are ready to earn in our team - contact us: [email protected] 

Copyright © 2011-2024 Buy-Pharm, Inc. All rights reserved.